The role of ATM in response to metformin treatment and activation of AMPK.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Acute COVID-19 and LongCOVID syndrome - molecular implications for therapeutic strategies - review.Frontiers in immunology · 2025
   Review
2. Understanding chronic inflammation: couplings between cytokines, ROS, NO, CaFrontiers in immunology · 2025
   Review
3. Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria.FEBS open bio · 2021
   Article
4. Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2.International journal of biological sciences · 2019
   Article
5. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.Nature reviews. Urology · 2017
   Review
6. A role for ataxia telangiectasia mutated in insulin-independent stimulation of glucose transport.Trends in cell & molecular biology · 2017
   Article
7. The genetics of drug efficacy: opportunities and challenges.Nature reviews. Genetics · 2016
   Review
8. Recent advances in the use of metformin: can treating diabetes prevent breast cancer?BioMed research international · 2015
   Review
9. Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention.Metabolites · 2013
   Article
10. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Clinical pharmacokinetics · 2013
    Review
11. The genetic and epigenetic basis of type 2 diabetes and obesity.Clinical pharmacology and therapeutics · 2012
    Review
12. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.Aging · 2012
    Article

Corrections and comments

• Comment on
  The role of ATM in response to metformin treatment and activation of AMPK.2012
• Comment on
  The role of ATM in response to metformin treatment and activation of AMPK.2012

Authors and funding

7 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as